07:00 , Sep 28, 2009 |  BC Week In Review  |  Clinical News

Pollinex Quattro Grass: Development ongoing

Allergy said that it was increasingly optimistic that FDA would lift a clinical hold on the company's clinical program for Pollinex Quattro allergy vaccines, citing a recent vote by an FDA panel in favor of...
07:00 , Sep 28, 2009 |  BC Week In Review  |  Clinical News

Pollinex Quattro Ragweed: Development ongoing

Allergy said that it was increasingly optimistic that FDA would lift a clinical hold on the company's clinical program for Pollinex Quattro allergy vaccines, citing a recent vote by an FDA panel in favor of...
07:00 , Sep 28, 2009 |  BC Week In Review  |  Clinical News

Pollinex Quattro Tree: Development ongoing

Allergy said that it was increasingly optimistic that FDA would lift a clinical hold on the company's clinical program for Pollinex Quattro allergy vaccines, citing a recent vote by an FDA panel in favor of...
07:00 , Mar 9, 2009 |  BC Week In Review  |  Clinical News

Pollinex Quattro Grass regulatory update

Allergy Therapeutics submitted an application in Germany seeking approval of Pollinex Quattro Grass vaccine for grass pollen allergy under the EU's Mutual Recognition Procedure. The subcutaneous vaccine is formulated with allergoids, tyrosine plus the tyrosine...
07:00 , Sep 29, 2008 |  BC Week In Review  |  Clinical News

Pollinex Quattro Ragweed: Phase III data

The North American Phase III R301 trial showed that Pollinex Quattro Ragweed vaccine met the primary endpoint of difference in combined symptom/medication score vs. placebo over the 4 peak pollen weeks. Vaccinated patients in the...
01:41 , Sep 23, 2008 |  BC Extra  |  Clinical News

Allergy's ragweed vaccine meets Phase III endpoint

Allergy (LSE:AGY) said its Pollinex Quattro Ragweed vaccine met the primary endpoint of a reduction in combined symptom/medication score in the Phase III R301 trial to treat ragweed pollen allergy. Vaccinated patients in the per...
07:00 , Jun 16, 2008 |  BC Week In Review  |  Clinical News

Pollinex Quattro Grass: Additional Phase III data

Allergy Therapeutics reported additional data from the double-blind, U.S., Canadian and European Phase III G301 trial in 1,028 patients. In patients with severe seasonal allergic rhino-conjunctivitis caused by grass pollen, Pollinex Quattro Grass vaccine reduced...
07:00 , May 19, 2008 |  BC Week In Review  |  Clinical News

Pollinex Quattro Grass: Phase III data

Pollinex Quattro Grass met the primary endpoint of a reduction in the combined symptom/medication score in the Phase III G301 trial to treat grass pollen allergy. Vaccinated patients in the intent-to-treat population had a 13%...
07:00 , Jul 30, 2007 |  BC Week In Review  |  Clinical News

Pollinex Quattro Ragweed: Phase III

AGY reported that the Phase III R301 trial of Pollinex Quattro Ragweed vaccine is "highly unlikely" to meet its primary endpoint of combined symptom and medication score. AGY said it now will be required to...
07:00 , Jul 16, 2007 |  BC Week In Review  |  Clinical News

Pollinex Quattro Grass: Phase III hold

Allergy Therapeutics plc (LSE:AGY), London, U.K.   AllerPharma Inc., Toronto, Ontario   Product: Pollinex Quattro Grass   Business: Inflammation   Molecular target: Not applicable   Description: Subcutaneous grass pollen allergy vaccine formulated with allergoids, tyrosine plus the toll-like...